Larissa Laska-ruebusch, PSY.D Psychologist - Clinical Child & Adolescent Medicare: Not Enrolled in Medicare Practice Location: 245 Kentucky St., Suite A, Pataluma, CA 94952 Phone: 707-216-1612 |
News Archive
Hotspur Technologies, Inc. announced today that it has received FDA clearance for the first three commercial products in its portfolio. These products are based on Hotspur's unique and groundbreaking technology that makes dialysis access interventional and peripheral vascular procedures that open blood vessels less expensive, more efficient, and less invasive for patients.
Simple changes in how we cook could go a long way towards preventing diabetes, say researchers at the Icahn School of Medicine at Mount Sinai.
A novel coronavirus, CoV-19, and a later phenotype CoV-2 were identified as the primary cause for severe acute respiratory syndrome (SARS CoV-2). The spike (S) protein of CoV-2 is one target for the development of a vaccine to prevent the viral entry into human cells. The inhibition of the direct interaction between ACE2 and the S-protein could provides a suitable strategy to prevent the membrane fusion of CoV-2 and the viral entry into human cells. Using MD simulations, we investigate the assembly process of a Coronavirus Spike protein fragment, the hexapeptide YKYRYL on the ACE2 receptor and its inhibitzory effect on the aggregation and activation of the CoV-2 spike receptor protein at the same receptor protein.
The city of London has launched an innovative service, funded by ESA, which delivers air pollution alerts and health advice via SMS text messages to those who suffer from asthma and other conditions vulnerable to poor air quality.
PDL BioPharma, Inc. announced today that it has completed the retirement of $61.7 million in aggregate principal amount of the Company's outstanding 2.75% Convertible Subordinated Notes, due August 16, 2023 for consideration consisting of the issuance of 11.1 million shares of the Company's common stock.
› Verified 5 days ago